{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:21:13Z","timestamp":1790850073682,"version":"4.1.0"},"reference-count":49,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BD"],"published-print":{"date-parts":[[2022,7,25]]},"abstract":"<jats:p>BACKGROUND: High body mass index (BMI) is regarded as a poor prognostic factor in breast cancer (BC). However, its association with pathological complete response (pCR) and survival after neoadjuvant chemotherapy (NAC) remains controversial. OBJECTIVE: We wanted to assess the prognostic impact of BMI in this setting. METHODS: Single-center, retrospective review of 314 BC patients undergoing NAC from 2010 to 2018. Patients were categorized as underweight\/normal weight (UW\/NW) (BMI &lt; 25) or overweight\/obese (OW\/OB) (BMI \u2265 25). The relationship between BMI and other traditional clinical-pathological prognostic variables with the pCR rate was investigated using logistic regression analysis. The effect on event-free survival (EFS) and overall survival (OS) was estimated by the Cox proportional hazards regression analysis. RESULTS: One hundred and twenty-two patients were UW\/NW while 192 were OW\/OB. Multivariate analysis revealed that hormonal receptors negative, HER2 positive, and clinical tumor stage (cT) 1\u20132 were independent predictor factors for pCR. Multivariate analysis confirmed tumor grade G3 and lack of pCR as independent adverse prognostic factors for EFS, while factors associated with worse OS were cT3-4, hormone receptors negative, and lack of pCR. Non-significant differences in pCR, EFS, or OS were observed between the two baseline BMI categories. CONCLUSIONS: In our experience, BMI is not associated with pCR, EFS, or OS in BC patients receiving NAC. Achieving pCR is the most consistent factor associated with EFS and OS. Prospective and well-designed studies taking into account other important biological and anthropometric factors are needed to determine the exact role of BMI in this setting.<\/jats:p>","DOI":"10.3233\/bd-210071","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T11:15:24Z","timestamp":1661512524000},"page":"351-361","source":"Crossref","is-referenced-by-count":5,"title":["Impact of body mass index on pathological complete response and survival of breast cancer patients receiving neoadjuvant chemotherapy"],"prefix":"10.1177","volume":"41","author":[{"given":"David","family":"Aguiar","sequence":"first","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ros","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Croissier","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mori","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Milena","family":"Vargas","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Galv\u00e1n","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Antonilli","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Saura","sequence":"additional","affiliation":[{"name":", Hospital Universitario de Gran Canaria Dr Negr\u00edn, , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"10","key":"10.3233\/BD-210071_ref1","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.3233\/BD-210071_ref2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/BCTT.S273058","article-title":"Approaching neoadjuvant therapy in the management of early-stage breast cancer","volume":"13","author":"Hyder","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"5","key":"10.3233\/BD-210071_ref3","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1245\/s10434-015-4404-8","article-title":"Pathological complete response in neoadjuvant treatment of breast cancer","volume":"22","author":"Cortazar","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.3233\/BD-210071_ref4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2015.02.011","article-title":"Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?","volume":"95","author":"Wang-Lopez","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"13","key":"10.3233\/BD-210071_ref5","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.3233\/BD-210071_ref6","doi-asserted-by":"publisher","first-page":"CD005002","DOI":"10.1002\/14651858.CD005002.pub2","article-title":"Preoperative chemotherapy for women with operable breast cancer","volume":"2007","author":"Van Der Hage","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.3233\/BD-210071_ref7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: Updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9938","key":"10.3233\/BD-210071_ref8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"18","key":"10.3233\/BD-210071_ref9","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","article-title":"Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy","volume":"48","author":"Houssami","year":"2012","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.3233\/BD-210071_ref10","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.3233\/BD-210071_ref11","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","article-title":"Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: A meta-analysis","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res"},{"key":"10.3233\/BD-210071_ref12","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrac028"},{"issue":"1","key":"10.3233\/BD-210071_ref13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11912-010-0139-7","article-title":"Obesity and cancer risk: recent review and evidence","volume":"13","author":"Basen-Engquist","year":"2011","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.3233\/BD-210071_ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0051446","article-title":"Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: A meta-analysis","volume":"7","author":"Cheraghi","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.3233\/BD-210071_ref15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer \u2013 viewpoint of the IARC Working Group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.3233\/BD-210071_ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3520"},{"issue":"1","key":"10.3233\/BD-210071_ref17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/13813450801954303","article-title":"Obesity and cancer: Pathophysiological and biological mechanisms","volume":"114","author":"Renehan","year":"2008","journal-title":"Arch Physiol Biochem"},{"issue":"12","key":"10.3233\/BD-210071_ref18","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/nrc3174","article-title":"Molecular mechanisms of cancer development in obesity","volume":"11","author":"Khandekar","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.3233\/BD-210071_ref19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1152\/physrev.00030.2014","article-title":"Obesity and diabetes: The increased risk of cancer and cancer-related mortality","volume":"95","author":"Gallagher","year":"2015","journal-title":"Physiol Rev"},{"key":"10.3233\/BD-210071_ref20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.breast.2019.02.001","article-title":"Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival","volume":"44","author":"Spei","year":"2019","journal-title":"Breast"},{"key":"10.3233\/BD-210071_ref21","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400469"},{"issue":"10","key":"10.3233\/BD-210071_ref22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","article-title":"Body mass index and survival in women with breast cancer\u2014systematic literature review and meta-analysis of 82 follow-up studies","volume":"25","author":"Chan","year":"2014","journal-title":"Ann Oncol"},{"key":"10.3233\/BD-210071_ref23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011220"},{"issue":"4","key":"10.3233\/BD-210071_ref24","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000496548","article-title":"Body mass index at diagnosis as a prognostic factor for early-stage invasive breast cancer after surgical resection","volume":"42","author":"Wang","year":"2019","journal-title":"Oncol Res Treat"},{"issue":"25","key":"10.3233\/BD-210071_ref25","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1200\/JCO.2007.14.4527","article-title":"Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer","volume":"26","author":"Litton","year":"2008","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.3233\/BD-210071_ref26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0041380","article-title":"Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.3233\/BD-210071_ref27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.breast.2017.04.001","article-title":"The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy","volume":"33","author":"Farr","year":"2017","journal-title":"Breast"},{"issue":"1","key":"10.3233\/BD-210071_ref28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clbc.2012.09.013","article-title":"Prognostic factors for triple-negative breast cancer patients receiving preoperative systemic chemotherapy","volume":"13","author":"Asaga","year":"2013","journal-title":"CLBC"},{"issue":"4","key":"10.3233\/BD-210071_ref29","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.clbc.2016.02.018","article-title":"BMI and pathologic complete response to neoadjuvant chemotherapy in breast cancer: A study and meta-analysis","volume":"16","author":"Erbes","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"10.3233\/BD-210071_ref30","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1634\/theoncologist.2012-0169","article-title":"The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer","volume":"17","author":"Del Fabbro","year":"2012","journal-title":"Oncologist"},{"issue":"1","key":"10.3233\/BD-210071_ref31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10549-014-2977-8","article-title":"Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients","volume":"146","author":"Arce-Salinas","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.3233\/BD-210071_ref32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.breast.2016.05.013","article-title":"Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients","volume":"32","author":"Karatas","year":"2017","journal-title":"The Breast"},{"issue":"6","key":"10.3233\/BD-210071_ref33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clbc.2016.06.008","article-title":"Effect of body mass index- and actual weight-based neoadjuvant chemotherapy doses on pathologic complete response in operable breast cancer","volume":"16","author":"Raman","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.3233\/BD-210071_ref34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-015-3287-5","article-title":"Impact of body mass index on neoadjuvant treatment outcome: A pooled analysis of eight prospective neoadjuvant breast cancer trials","volume":"150","author":"Fontanella","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.3233\/BD-210071_ref35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00432-008-0428-9","article-title":"Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger","volume":"135","author":"Eralp","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"issue":"18","key":"10.3233\/BD-210071_ref36","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1002\/cncr.26019","article-title":"Impact of body mass index on clinical outcomes in triple-negative breast cancer","volume":"117","author":"Ademuyiwa","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.3233\/BD-210071_ref37","doi-asserted-by":"publisher","first-page":"427","DOI":"10.4048\/jbc.2012.15.4.427","article-title":"Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: Korean data","volume":"15","author":"Lee","year":"2012","journal-title":"J Breast Cancer"},{"issue":"7","key":"10.3233\/BD-210071_ref38","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.5858\/134.7.e48","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)","volume":"134","author":"Hammond","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"31","key":"10.3233\/BD-210071_ref39","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast: American Society of Clinical Oncology\/College of American Pathologists Clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.3233\/BD-210071_ref41","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jnci\/djn151","article-title":"Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer","volume":"100","author":"Mart\u00edn","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.3233\/BD-210071_ref42","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1078-0432.CCR-16-0162","article-title":"Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.3233\/BD-210071_ref43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2010.29.7614","article-title":"Effect of obesity on prognosis after early-stage breast cancer","volume":"29","author":"Ewertz","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.3233\/BD-210071_ref44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/annonc\/mdu509","article-title":"Obesity and the outcome of young breast cancer patients in the UK: The POSH study","volume":"26","author":"Copson","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.3233\/BD-210071_ref45","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archinte.165.11.1267","article-title":"Undertreatment of obese women receiving breast cancer chemotherapy","volume":"165","author":"Griggs","year":"2005","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.3233\/BD-210071_ref46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JOP.0832001","article-title":"Chemotherapy dosing strategies in the obese, elderly, and thin patient: Results of a nationwide survey","volume":"4","author":"Field","year":"2008","journal-title":"J Oncol Pract"},{"issue":"24","key":"10.3233\/BD-210071_ref47","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.3233\/BD-210071_ref48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"7485","key":"10.3233\/BD-210071_ref49","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/bmj.38314.622095.8F","article-title":"30 Years\u2019 follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study","volume":"330","author":"Bonadonna","year":"2005","journal-title":"Br Med J"},{"issue":"1","key":"10.3233\/BD-210071_ref50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/cam4.571","article-title":"Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients","volume":"5","author":"Iwase","year":"2016","journal-title":"Cancer Med"}],"container-title":["Breast Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/BD-210071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:32:24Z","timestamp":1777383144000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/BD-210071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":49,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/bd-210071","relation":{},"ISSN":["0888-6008","1558-1551"],"issn-type":[{"value":"0888-6008","type":"print"},{"value":"1558-1551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]}}}